strippokerwebgame| Johnson & Johnson's legendary biological CAR-T therapy gets EU approval again

Legendary creatures announceStrippokerwebgameThe European Commission (EC) has approved cilta-cel (trade name Carvykti) for the treatment of adult patients with recurrent and refractory multiple myeloma who have previously received at least first-line treatment (including a proteasome inhibitor and an immunomodulator) and have progressed at the last treatment and are resistant to lenalidomide. Cedacil is a CAR-T therapy targeting B cell maturation antigen (BCMA). In December 2017, Johnson & Johnson's Johnson Innovation Pharmaceuticals (Johnson & Johnson Innovative Medicine) signed an exclusive global license and cooperation agreement with legendary to develop and commercialize Cedar Oren.

In February 2022, Cedarkey Orensi was approved by FDA in the United States and conditionally approved by EC in May for the treatment of adult patients with recurrent or refractory multiple myeloma who had received at least three previous treatments. FDA also approved Cedalenil on April 5 this year for the treatment of adult patients with recurrent or refractory multiple myeloma who have previously received at least one treatment (including a proteasome inhibitor and an immunomodulator) and are resistant to lenalidomide.

In China, legendary Biology's application for the marketing of a new drug for Cedar Orenser injection has been included in the priority review by NMPA, and the proposed indications are: for the treatment of adult patients with recurrent or refractory multiple myeloma (R MM) after previous treatment with a proteasome inhibitor and an immunomodulator.

Tags:

Prev: governorofpoker3youdagames| How to invest based on fund trends
Next: unrealengineblockchain| The supply of soda ash has steadily increased, and the profit of ammonia soda enterprises is 256 yuan/ton: the price difference between Shahe and North China markets is 200 yuan